CME Company Insiders

CME Stock  USD 209.65  1.23  0.59%   
About 69% of CME's corporate insiders are selling. The analysis of the overall insider sentiment regarding CME Group suggests that many insiders are alarmed. CME employs about 3.6 K people. The company is managed by 63 executives with a total tenure of roughly 632 years, averaging almost 10.0 years of service per executive, having 56.59 employees per reported executive.
Cees Vermaas  CEO
Managing Director & CEO of CME Europe Limited
Phupinder Gill  CEO
CEO, Director, Member of Competitive Markets Advisory Council, Member of Executive Committee and Member of Strategic Steering Committee

CME's Insider Buying Vs Selling

31

 
Selling
 
Buying

Latest Trades

2024-03-26William R ShepardAcquired 12 @ 214.71View
2024-01-31Timothy Francis MccourtDisposed 35 @ 206.78View
2024-01-23Kathy E. ManningAcquired @ 203.97
2024-01-18William R ShepardAcquired 59 @ 202.44View
2024-01-17Thomas R. CarperAcquired @ 202.97
2023-12-28William R ShepardAcquired 12 @ 210.79View
2023-12-11Bryan T DurkinDisposed 5560 @ 216.37View
2023-12-06Michael C. BurgessDisposed @ 214.25
2023-12-04Derek SammannDisposed 1862 @ 222.07View
2023-12-01Derek SammannDisposed 10681 @ 220.5View
2023-11-06Dennis SuskindDisposed 1500 @ 213.6View
2023-10-31Timothy Francis MccourtDisposed 43 @ 213.18View
2023-10-30Elizabeth A CookDisposed 500 @ 211.43View
2023-10-26Timothy Francis MccourtDisposed 1043 @ 216.37View
2023-09-27William R ShepardAcquired 12 @ 199.84View
2023-08-18Terrence A DuffyDisposed 30000 @ 203.95View
2023-08-15Julie HolzrichterDisposed 6000 @ 205.47View
2023-08-11Timothy S BitsbergerDisposed 800 @ 205.92View
2023-08-10Julie WinklerDisposed 6262 @ 207View
Monitoring CME's insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.

Acquired vs Disposed

Filed vs Not Filed

Insider sentiment refers to the collective sentiment or feeling of CME's insiders - typically its officers, directors, and beneficial owners holding more than a certain percentage of the company's stock - about the future prospects of CME Group. This sentiment is often gauged based on the trading activities of these insiders. If insiders are purchasing more shares of their own company, it may be interpreted as a bullish sentiment, indicating that they believe CME's stock will rise in value. Conversely, if insiders are selling shares, it might be seen as bearish, suggesting they expect the stock price to drop.
  
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in CME Group. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population.

CME's Workforce Through the Years

Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with CME's future performance. Based on our forecasts, it is anticipated that CME will maintain a workforce of about 3570 employees by May 2024.
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid

CME's latest congressional trading

Congressional trading in companies like CME Group, is subject to rigorous scrutiny to prevent conflicts of interest and insider trading. This is governed by multiple SEC regulations which were established to foster transparency and deter members of Congress from leveraging non-public information for personal gain. This oversight helps maintain public trust and ensures that investments in CME by those in governmental positions are based on the same information available to the general public.
2024-01-23Representative Kathy ManningAcquired Under $15KVerify
2024-01-17Senator Thomas R CarperAcquired Under $15KVerify
2023-12-06Representative Michael C. BurgessDisposed $15K to $50KVerify
2023-05-25Representative Zoe LofgrenDisposed Under $15KVerify
2023-01-31Representative Daniel GoldmanAcquired Under $15KVerify
2023-01-11Senator Thomas R. CarperAcquired Under $15KVerify
2021-12-14Representative Robert J. WittmanDisposed Under $15KVerify
2021-06-22Representative John CurtisDisposed Under $15KVerify
2021-03-08Representative Ro KhannaAcquired Under $15KVerify
2020-09-23Representative Dean PhillipsAcquired Under $15KVerify
2020-09-04Representative Kurt SchraderDisposed Under $15KVerify
2020-07-10Representative Donald S. Beyer, Jr.Disposed Under $15KVerify
2020-07-01Representative John A. YarmuthDisposed Under $15KVerify
2020-03-19Senator Kelly LoefflerAcquired $50K to $100KVerify
2020-02-20Representative Mikie SherrillDisposed Under $15KVerify
2019-03-11Senator Shelley Moore CapitoAcquired Under $15KVerify
2018-04-24Senator Shelley M CapitoAcquired $15K to $50KVerify
2017-01-05Representative Thomas SuozziDisposed Under $15KVerify
2014-07-23Senator Susan M CollinsAcquired Under $15KVerify
2014-07-23Senator Susan M. CollinsAcquired Under $15KVerify

CME Management Team Effectiveness

The company has Return on Asset of 0.0142 % which means that on every $100 spent on assets, it made $0.0142 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.1203 %, implying that it generated $0.1203 on every 100 dollars invested. CME's management efficiency ratios could be used to measure how well CME manages its routine affairs as well as how well it operates its assets and liabilities. At present, CME's Return On Capital Employed is projected to increase slightly based on the last few years of reporting. The current year's Return On Assets is expected to grow to 0.03, whereas Return On Equity is forecasted to decline to 0.12. At present, CME's Non Currrent Assets Other are projected to decrease significantly based on the last few years of reporting. The current year's Total Current Assets is expected to grow to about 99.6 B, whereas Other Assets are forecasted to decline to about 127.7 M.

CME Quarterly Income Before Tax

1.01 Billion

The current year's Net Income Applicable To Common Shares is expected to grow to about 3.2 B, whereas Common Stock Shares Outstanding is forecasted to decline to about 311.9 M.

CME Workforce Comparison

CME Group is rated below average in number of employees category among related companies. The total workforce of Financials industry is currently estimated at about 98,041. CME holds roughly 3,565 in number of employees claiming about 4% of equities under Financials industry.

CME Profit Margins

The company has Net Profit Margin of 0.58 %, which implies that it may need a different competitive strategy as even a very small decline in it revenue may erase profits and result in a net loss. This is way below average. In the same way, it shows Net Operating Margin of 0.62 %, which entails that for every 100 dollars of revenue, it generated $0.62 of operating income.
Current ValueLast YearChange From Last Year 10 Year Trend
Gross Profit Margin0.920.8139
Moderately Up
Pretty Stable

CME Insider Trading History

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific CME insiders, such as employees or executives, is commonly permitted as long as it does not rely on CME's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, CME insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Buy/Sell Ratio# Purchases Trades# Sales TradesTotal Shares PurchasedTotal Shares Sold
2024-03-01
0.7895
15
19
 88,570 
 39,610 
2023-12-01
0.2857
4
14
 2,544 
 37,767 
2023-09-01
0.4516
14
31
 63,176 
 80,948 
2023-03-01
1.6
8
5
 5,739 
 2,021 
2022-12-01
4.0
8
2
 50,871 
 20,531 
2022-09-01
0.303
10
33
 59,369 
 25,508 
2022-03-01
1.2727
42
33
 38,691 
 51,059 
2021-12-01
0.375
9
24
 6,068 
 35,256 
2021-09-01
0.2222
12
54
 61,180 
 27,032 
2021-06-01
1.75
21
12
 13,401 
 49,520 
2021-03-01
0.4828
14
29
 125,536 
 95,895 
2020-12-01
0.0526
1
19
 2,500 
 51,489 
2020-09-01
0.2143
12
56
 68,100 
 46,497 
2020-06-01
1.6429
23
14
 19,322 
 15,701 
2020-03-01
0.7273
32
44
 166,550 
 91,851 
2019-12-01
0.25
1
4
 506.00 
 42,980 
2019-09-01
0.2167
13
60
 50,805 
 85,894 
2019-06-01
0.8
28
35
 50,440 
 88,671 
2019-03-01
0.625
30
48
 142,828 
 110,984 
2018-12-01
0.3333
6
18
 6,034,953 
 45,201 
2018-09-01
0.6296
34
54
 68,621 
 58,482 
2018-06-01
1.4286
20
14
 19,619 
 41,472 
2018-03-01
0.6176
21
34
 135,822 
 113,378 
2017-12-01
0.2273
5
22
 28,545 
 67,609 
2017-09-01
0.4211
16
38
 102,991 
 92,145 
2017-06-01
1.0
34
34
 60,596 
 76,359 
2017-03-01
0.6
21
35
 125,699 
 80,146 
2016-12-01
0.3636
12
33
 104,036 
 196,801 
2016-09-01
0.3
21
70
 152,253 
 167,853 
2016-06-01
1.7647
30
17
 82,734 
 121,365 
2016-03-01
0.5833
21
36
 171,257 
 106,729 
2015-12-01
0.25
1
4
 11,250 
 25,724 
2015-09-01
0.3077
16
52
 96,890 
 92,575 
2015-06-01
1.2857
36
28
 53,744 
 74,646 
2015-03-01
0.4865
18
37
 97,399 
 170,253 
2014-12-01
0.4091
9
22
 26,980 
 42,704 
2014-09-01
0.6122
30
49
 101,882 
 93,548 
2014-06-01
3.75
15
4
 64,750 
 100,000 
2014-03-01
0.1667
4
24
 33,694 
 68,577 
2013-12-01
0.1765
3
17
 22,525 
 37,257 
2013-09-01
0.2128
10
47
 59,072 
 40,645 
2013-06-01
1.0556
19
18
 60,521 
 86,185 
2013-03-01
0.8824
15
17
 70,116 
 64,354 
2012-09-01
0.3333
12
36
 73,870 
 38,329 
2012-06-01
2.25
18
8
 6,793 
 9,900 
2012-03-01
0.8125
13
16
 13,520 
 18,970 
2011-12-01
1.0
2
2
 319.00 
 90.00 
2011-09-01
2.3333
21
9
 32,797 
 11,643 
2011-06-01
1.3571
19
14
 4,988 
 6,016 
2011-03-01
1.2
6
5
 3,984 
 3,954 
2010-12-01
0.2727
3
11
 502.00 
 2,257 
2010-09-01
2.1818
24
11
 59,068 
 3,875 
2010-06-01
1.3571
19
14
 5,608 
 8,885 
2010-03-01
0.4375
7
16
 2,132 
 5,331 
2009-12-01
0.3
3
10
 893.00 
 8,623 
2009-09-01
2.625
21
8
 33,281 
 6,748 
2009-06-01
0.5122
21
41
 5,966 
 21,604 
2009-03-01
7.0
7
1
 1,495 
 100.00 
2008-12-01
1.5
21
14
 15,713 
 4,937 
2008-09-01
4.0
4
1
 46,359 
 48.00 
2008-06-01
4.625
37
8
 27,244 
 3,107 
2008-03-01
0.6923
9
13
 6,679 
 12,120 
2007-12-01
0.4762
10
21
 24,110 
 43,038 
2007-09-01
1.0
30
30
 78,722 
 19,450 
2007-06-01
1.8333
33
18
 26,291 
 15,165 
2007-03-01
0.3913
9
23
 7,960 
 29,240 
2006-12-01
0.6875
11
16
 24,685 
 40,690 
2006-09-01
1.0
17
17
 8,945 
 20,593 
2006-06-01
1.5652
36
23
 32,180 
 40,490 
2006-03-01
0.3
12
40
 13,301 
 34,619 
2005-12-01
0.0884
13
147
 31,950 
 68,900 
2005-09-01
0.1212
8
66
 10,600 
 47,648 
2005-06-01
0.5077
33
65
 28,817 
 50,277 
2005-03-01
0.1429
7
49
 9,500 
 23,299 
2004-12-01
0.0435
2
46
 17,000 
 58,000 
2004-06-01
2.0
14
7
 49,100 
 54,600 
2004-03-01
1.3333
4
3
 12,000 
 7,000 
2003-12-01
0.5
6
12
 53,800 
 113,490 
2003-09-01
1.3333
4
3
 101,683 
 112,733 
2003-06-01
1.0
4
4
 41,500 
 65,450 

CME Notable Stakeholders

A CME stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as CME often face trade-offs trying to please all of them. CME's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting CME's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Cees VermaasManaging Director & CEO of CME Europe LimitedProfile
Phupinder GillCEO, Director, Member of Competitive Markets Advisory Council, Member of Executive Committee and Member of Strategic Steering CommitteeProfile
Leo MelamedChairman EmeritusProfile
Charles CareyVice Chairman of the BoardProfile
Terrence DuffyExecutive Chairman and President Member of Competitive Markets Advisory Council, Chairman of Executive Committee and Member of Strategic Steering CommitteeProfile
Sunil CutinhoPresident - CME ClearingProfile
Kimberly TaylorPresident of Global Operations, Technology and RiskProfile
Ana DutraIndependent DirectorProfile
Daniel GlickmanIndependent DirectorProfile
Howard SiegelIndependent DirectorProfile
Dennis ChookaszianIndependent DirectorProfile
Steven WollackIndependent DirectorProfile
William MillerIndependent DirectorProfile
Gedon HertshtenIndependent DirectorProfile
Daniel KayeDirectorProfile
Douglas MoniesonIndependent DirectorProfile
Jeffrey BernacchiIndependent DirectorProfile
James OliffIndependent DirectorProfile
Timothy BitsbergerIndependent DirectorProfile
Patrick MaloneyIndependent DirectorProfile
Dennis SuskindIndependent DirectorProfile
Alex PollockLead Independent DirectorProfile
David WescottIndependent DirectorProfile
Edemir PintoIndependent DirectorProfile
Deborah LucasIndependent DirectorProfile
John SandnerDirectorProfile
Larry GerdesIndependent DirectorProfile
Terry SavageIndependent DirectorProfile
Bruce JohnsonIndependent DirectorProfile
Ronald PankauIndependent DirectorProfile
Yra HarrisDirectorProfile
Michael SpencerDirectorProfile
Martin GepsmanIndependent DirectorProfile
William ShepardIndependent DirectorProfile
Kathleen CroninSenior Managing Director, General Counsel, Corporate SecretaryProfile
Derek SammannSenior Managing Director - Financial Products and ServicesProfile
William KnottenbeltSenior Managing Director, Europe, Middle East, Africa (EMEA)Profile
John PietrowhiczSenior Managing Director - Business Development and Corporate FinanceProfile
Julie HolzrichterCOO and Sr. Managing DirectorProfile
Bryan DurkinChief Commercial Officer and Sr. Managing DirectorProfile
Hilda PiellChief Human Resource Officer, Senior Managing DirectorProfile
Jack TobinChief Accounting Officer, Managing DirectorProfile
Linda RichSenior Managing Director - Government Relations and Legislative AffairsProfile
Julie WinklerSenior Managing Director - Research and Product DevelopmentProfile
Kevin KometerCIO, Senior Managing DirectorProfile
Robert ZagottaSenior Managing Director - Products and ServicesProfile
Jill HarleyManaging DirectorProfile
Sean TullySenior Managing Director - Interest Rates, OTC ProductsProfile
Kendal VromanChief OfficerProfile
Michel EveraertMD EMEAProfile
Sean KeatingMD OfficeProfile
Elizabeth CookIndependent TrusteeProfile
Anita LiskeySenior CommunicationsProfile
Jonathan MarcusSenior CounselProfile
Lynne FitzpatrickChief OfficerProfile
Edward GogolManaging SolutionsProfile
John PeschierManaging RelationsProfile
Jason WellerManaging StrategyProfile
William HobertIndependent TrusteeProfile
Christopher BowenChief MDProfile
Elizabeth GischManaging ManagementProfile
Eileen KeeveManaging DevelProfile
Kevin LennonManaging EstateProfile

About CME Management Performance

The success or failure of an entity such as CME Group often depends on how effective the management is. CME management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of CME management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the CME management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last ReportedProjected for Next Year
Return On Tangible Assets 0.03  0.06 
Return On Capital Employed 0.09  0.17 
Return On Assets 0.02  0.03 
Return On Equity 0.12  0.12 
The data published in CME's official financial statements usually reflect CME's business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of CME Group. For example, before you start analyzing numbers published by CME accountants, it's critical to develop an understanding of what CME's liquidity, profitability, and earnings quality are in the context of the Capital Markets space in which it operates.
Please note, the presentation of CME's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, CME's management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in CME's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of CME Group. Please utilize our Beneish M Score to check the likelihood of CME's management manipulating its earnings.

CME Workforce Analysis

Traditionally, organizations such as CME use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare CME within its industry.

CME Manpower Efficiency

Return on CME Manpower

Revenue Per Employee1.6M
Revenue Per Executive88.6M
Net Income Per Employee906K
Net Income Per Executive51.3M
Working Capital Per Employee413.3K
Working Capital Per Executive23.4M
When determining whether CME Group is a strong investment it is important to analyze CME's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact CME's future performance. For an informed investment choice regarding CME Stock, refer to the following important reports:
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in CME Group. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population.
You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.

Complementary Tools for CME Stock analysis

When running CME's price analysis, check to measure CME's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CME is operating at the current time. Most of CME's value examination focuses on studying past and present price action to predict the probability of CME's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move CME's price. Additionally, you may evaluate how the addition of CME to your portfolios can decrease your overall portfolio volatility.
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Is CME's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of CME. If investors know CME will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about CME listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
0.276
Dividend Share
4.4
Earnings Share
8.85
Revenue Per Share
15.512
Quarterly Revenue Growth
0.192
The market value of CME Group is measured differently than its book value, which is the value of CME that is recorded on the company's balance sheet. Investors also form their own opinion of CME's value that differs from its market value or its book value, called intrinsic value, which is CME's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because CME's market value can be influenced by many factors that don't directly affect CME's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between CME's value and its price as these two are different measures arrived at by different means. Investors typically determine if CME is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, CME's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.